Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 5/20 | 0.33 |
| ▸ | FAAH | O00519 | 3/20 | 0.30 |
| ▸ | CES2 | O00748 | 2/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827904 | 0.92 | APP (0.37) | APPCES1PTGS1PDE4ALMNA | |
| SCHEMBL31091256 | 0.90 | APP (0.35) | APP | |
| 1,4-Butanediol SCHEMBL2058127 | 0.88 | APP (0.31) | APP | |
| 1,3-Propanediol SCHEMBL2057583 | 0.88 | APP (0.31) | APP | |
| SCHEMBL18284250 | 0.88 | APP (0.39) | APPCES1FAAHCES2PTGS1 | |
| SCHEMBL2058000 | 0.86 | CES1 (0.38) | APPCES1FAAHCES2 | |
| SCHEMBL27621286 | 0.86 | APP (0.38) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL15670443 | 0.85 | APP (0.41) | APPCES1PTGS1PDE4ALMNA | |
| SCHEMBL27864713 | 0.85 | APP (0.34) | APP | |
| SCHEMBL781199 | 0.83 | PTGS1 (0.35) | APPPTGS1PDE4ALMNASLC6A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956031-B2 | 11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-10-18 | — | — | US | disclosed |
| EP-1490393-A1 | 11BETA-SUBSTITUTED 19-NOR-17ALPHA-PREGNA-1,3,5(10)-TRIEN-17BETA-OLS WITH A 21,16ALPHA-LACTONE RING | Schering AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| US-20040014735-A1 | 11-Beta substituted 19-nor-17-alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring | SCHERING AG (DE) | 2004-01-22 | — | — | US | disclosed |
| WO-2003080642-A1 | 11BETA-SUBSTITUTED 19-NOR-17ALPHA-PREGNA-1,3,5(10)-TRIEN-17BETA-OLS WITH A 21,16ALPHA-LACTONE RING | SCHERING AG (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014735-A1 | 11-Beta substituted 19-nor-17-alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring | HSD17B11, CYP19A1, NR5A1 | APP 4037/4885CES1 167/4885FAAH 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.